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Background: Given the increase in life expectancy among HIV-positive individuals attributable to antiretroviral
therapies, cigarette smoking now represents one of the most salient health risks confronting the HIV-positive
population. Despite this risk, very few efforts to date have been made to target persons living with HIV for smoking
cessation treatment, and no efforts have been made to explore the role of cognitions and HIV disease events/stages
on smoking outcomes. The purpose of the study, Project STATE (Study of Tobacco Attitudes and Teachable Events),
is to prospectively examine the relationship between HIV events/stages, perceived impact of HIV disease, attitudes
about cigarette smoking, and smoking behaviors.
Methods/Design: This study employs a prospective design. Patients are recruited at the time of their first physician
visit at a large inner city HIV-clinic – Thomas Street Health Center (TSHC). Consenting participants then complete a
baseline assessment. All participants are offered standard care smoking cessation treatment. Follow-up assessments
are completed on four subsequent occasions: 3, 6, 9, and 12 months post-baseline. These follow-up assessments
are scheduled to coincide with routine clinic appointments with their TSHC physicians. In addition, each participant
is given a prepaid cell phone at the time of enrollment and asked to complete brief phone assessments weekly for
the first three months of the study period.
Discussion: By evaluating events/stages of HIV disease as potential teaching moments for smoking cessation,
findings from this study could be used to develop treatments tailored to an individual’s stage of HIV disease. This
study design will enable us to carefully track changes in smoking behavior over time, and to link these changes to
both the course of HIV disease and/or to the participant’s’ perceived impact of HIV. By identifying optimal time points
for intervention, the findings from this study will have the potential to maximize the efficiency and efficacy of cessation
treatments delivered in resource-limited settings. In addition, the findings will be instrumental in identifying specific
constructs that should be targeted for intervention and will provide a strong foundation for the development of future
cessation interventions targeting smokers living with HIV/AIDS.
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Available data suggest that the prevalence of cigarette
smoking is significantly higher in HIV-positive popu-
lations compared to the general population in the US
(currently estimated to be 19.0%) [1]. Data from one of
our earlier studies indicated that almost 50% of indivi-
duals receiving treatment at a large, Houston, Texas-area* Correspondence: dvidrine@mdanderson.org
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unless otherwise stated.HIV/AIDS clinic were current smokers. Similarly high
rates of smoking (50-65%) have been reported by others
[2,3]. While the exact reasons for the elevated prevalence
of smoking in the HIV-positive population are not known,
there are several plausible explanations. Individuals of low
socioeconomic status are both more likely to smoke and
more likely to become infected with HIV. Other variables
associated with both smoking status and HIV include gay
or bisexual orientation [4,5], alcohol and/or illicit drug use
[6], and depression [7].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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merous adverse health outcomes (e.g., cancer, stroke,
heart disease, and chronic obstructive pulmonary di-
sease), a growing body of literature provides strong evi-
dence that people living with HIV/AIDS (PLWHA) are
especially at risk. For example, HIV-positive smokers
have an increased incidence of several pulmonary dis-
eases, including cryptococcus [8], invasive pneumococcal
disease [9,10], and spontaneous pneumothorax [11]. Even
in the absence of an AIDS-related pulmonary condition,
HIV-positive smokers are significantly more likely to
experience respiratory symptoms compared to HIV-
negative smokers [12]. Smokers living with HIV/AIDS
also have an increased risk of several HIV/AIDS-
related oral diseases [13-15]. In fact, several recent
studies indicate that smoking among PLWHA repre-
sents one of the leading causes of morbidity and mor-
tality, and effective smoking cessation efforts could
significantly increase life expectancy [16,17].
The data supporting the adverse effects of cigarette
smoking and elevated prevalence of smoking among
PLWHA are striking. Given the increase in life expect-
ancy among HIV-positive individuals attributable to
antiretroviral therapies, cigarette smoking now repre-
sents one of the most salient health risks confronting
the HIV-positive population. Despite this risk, very few
efforts to date have been made to target PLWHA for
smoking cessation treatment, and no efforts have been
made to explore the role of cognitions and HIV disease
events/stages on smoking outcomes. Thus, the overarching
goal of this National Cancer Institute R01-funded study
(5R01 CA132636-04) is to prospectively explore the rela-
tionship between HIV events/stages, perceived impact of
HIV disease, attitudes about cigarette smoking, and smok-
ing behaviors. The specific aims of the study are to: 1) as-
sess the relationship between HIV disease event/stage (i.e.,
diagnosis, stable, and progressive disease) and smoking out-
comes (i.e., intention to quit, number of quit attempts, and
cessation outcomes); 2) evaluate perceived impact of HIV
as a potential mediator of the association between disease
stage and smoking outcomes; 3) evaluate potential media-
tors (i.e., attitudes about smoking) and moderators (i.e.,
perceived control and social norms) of the relationship be-
tween perceived impact of HIV-disease and smoking out-
comes; and 4) describe, in detail, the smoking behavior




Project STATE (Study of Tobacco Attitudes and Teach-
able Events) is currently underway and employs a pro-
spective design to examine the relationship between HIV
events/stages, perceived impact of HIV disease, attitudesabout cigarette smoking, and smoking behaviors. To ac-
complish this goal, we identify and recruit smokers from
Thomas Street Health Center (TSHC), a Harris Health
clinic in Houston, TX that provides primary and spe-
cialty HIV care to approximately one third of PLWHA
in Harris County. TSHC provides care to approximately
5,000 PLWHA. After being offered a brief standard care
smoking cessation intervention (see Procedures section),
research participants complete a computer-administered
assessment designed to measure perceived impact of HIV,
attitudes about smoking, and current smoking behavior at
the time of study enrollment. Participants are then fol-
lowed over a one-year period and asked to complete
follow-up computer-administered assessments at three-
month intervals. In addition to the clinic-administered as-
sessments, participants complete brief, weekly cell phone
assessments for the first 3 months following study enroll-
ment. The phone-based data collection approach enables
us to gather detailed information on both the magnitude
and duration of the teachable moment effect in this cri-
tical period of time following HIV care initiation. Fi-
nally, research staff conduct detailed electronic medical
record reviews to document relevant disease- and treatment-
related variables.Study site and participants
The University of Texas MD Anderson Cancer Center
Institutional Review Board approved the study. Eligible
participants are 18 years of age or older, new patients of
the TSHC clinic, self-reported current smokers at the
time of enrollment, able to perform written informed
consent and English or Spanish speaking. Participants
are excluded if their physician deems them ineligible due
to medical or psychiatric conditions.
The target sample size is 450 participants. This esti-
mate is based on the number of newly diagnosed, anti-
retroviral naïve patients seen at TSHC each month (n =
50), the expected prevalence of current smoking (50%),
and the expected participation rate. Each month, ap-
proximately 75 new patients are seen at TSHC. Of these,
approximately 50 will meet our operational definition of
newly HIV diagnosed (i.e., diagnosed with HIV within
the past 3 months and antiretroviral naïve).Procedures
Recruitment
New clinic patients are identified through electronic me-
dical record review. Research staff approach all new pa-
tients at their first physician visit and assess current
smoking status (i.e., smoked 100 or more cigarettes in
lifetime, and smoke every day or most days). Patients
that report being a current smoker and meet the other
eligibility criteria are offered enrollment.
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Research staff administer an audio computer assisted
self-interview (ACASI) to all participants (see Measures
section below for a full description of interview measures).
The interview takes approximately 30–45 minutes to
complete and answers are recorded directly into a comput-
erized database that contains programmed logic checks and
skip patterns. At this time, participants also complete the
Mini Mental Status Examination and a breath carbon mon-
oxide test. After completing the entire baseline assessment,
participants are compensated with a $25 gift card.
Follow-up assessments
Follow-up assessments are conducted at TSHC at 3, 6,
9, and 12 months post-baseline. These assessments are
scheduled to coincide with scheduled clinic appointments
in order to reduce study-related burden. Procedures to re-
duce attrition include: 1) reminder phone calls; 2) offering
follow-up assessments on different days/times to accom-
modate different schedules; and 3) obtaining the names
and phone numbers of at least three collaterals (i.e.,
friends or relatives). Follow-ups mirror the baseline as-
sessment, consisting of the ACASI, and carbon monox-
ide (CO) test. Participants receive a $25 gift card for
each completed follow-up assessment.
Cell phone assessments
A novel component of our proposed design is cell phone
data collection, which occurs weekly during the first 3
months of study enrollment (i.e., the 3-month period of
time following the HIV diagnosis). We hypothesize that
the time of HIV diagnosis (or initiation of HIV care) is
the strongest teachable moment for smoking cessation.
Thus, the cell phone assessments allow for the collection
of detailed information on both the magnitude and dur-
ation of the teachable moment effect in this critical
period of time. These brief assessments collect informa-
tion on the participant’s perceived disease impact, at-
titudes about smoking (i.e., quit motivation and risk
perceptions/outcome expectancies) and smoking out-
comes (smoking status and intention to quit). To ensure
feasibility of this methodological approach, we provide
prepaid cell phones to all participants. Prepaid minutes
are loaded onto these phones, as needed, to complete
the brief assessments. Following completion of the study,
participants are allowed to keep the phones. In previous
studies, we have used this approach very effectively.
Smoking cessation treatment
The goal of the study is not to assess the efficacy or ef-
fectiveness of a smoking cessation intervention. How-
ever, due to the overwhelming evidence of adverse
effects for continued smoking among PLWHA, all par-
ticipants are provided with information about the smokingcessation resources available at the clinic. Participants
who continue to smoke at the time of follow-up assess-
ments are again offered this usual care treatment.
Conceptual framework
The conceptual framework for this study (see Figure 1)
draws heavily from the teachable moment heuristic pro-
posed by McBride and colleagues [18], and from major
theories of health behavior change such as the Health
Belief Model [19], Social Cognitive Theory [20], the The-
ory of Reasoned Action/Planned Behavior [21], and
stress responses (i.e., the Cognitive Activation Theory of
Stress and the Self-Regulatory Model) [22,23]. A teach-
able moment event is thought to motivate individuals to
adopt risk-reducing behaviors that will improve their
health or reduce their risk of adverse health outcomes
[18]. It is possible that HIV events/stages serve as “teach-
able moments” (McBride) when PLWHA have increased
motivation and self-efficacy, leading to an increased likeli-
hood of smoking cessation. An HIV-related event, such as
the initiation of HIV care, will trigger a cognitive stress re-
sponse and increase one’s perceived impact of HIV, lead-
ing to an increase in risk perception, motivation to quit
smoking and beliefs that smoking cessation with improve
HIV-related health. These same attitudes about smoking
are expected to directly increase intentions to quit smo-
king, to facilitate cessation attempts and increase the like-
lihood of successful cessation.
Because we hypothesize that the HIV diagnosis (or care
initiation) elicits the greatest perceived impact during
an individual’s HIV disease course, we expect this
event to be associated with the largest change in smok-
ing outcomes (i.e., the highest number of quit at-
tempts, stronger intentions to quit and higher rates of
cessation). We further hypothesize that the time of dis-
ease progression - identified by treatment failure or
diagnosis of an HIV-related disease - is associated with
high levels of perceived impact (but not as high as the
time of HIV diagnosis) and also elicits changes in
smoking outcomes. Finally, when the disease is stable,
the perceived impact of HIV is expected to be relatively
low compared to the time of HIV diagnosis and HIV
disease progression. Thus, it is unlikely for changes in
smoking outcomes to be observed during periods of
HIV disease stability.
The framework also suggests that individuals who find
an HIV-related event (e.g., HIV diagnosis) to have little
impact on their lives will be unlikely to experience a
change in smoking attitudes or smoking outcomes. Fi-
nally, the framework suggests that two domains, subject-
ive norms and perceived control, will moderate the
relationship between the perceived impact of HIV and
smoking outcomes. For example, an individual who per-
ceives an event to be of high impact and has a high level
Figure 1 Conceptual framework for the association between HIV events/stages and smoking.
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than a participant who perceives a high impact of dis-
ease but has a lower level of self-efficacy.
Measures
Perceived impact of HIV/AIDS
Two measures are used to assess the participant’s per-
ceived impact of HIV/AIDS. The Brief Illness Perception
Questionnaire (Brief-IPQ) is used to measure cognitive
and emotional illness representations. This short 8-item
measure was designed to evaluate key domains (i.e., con-
sequences, personal control, treatment control, identity,
concern, and understanding) involved in an individual’s
response to a health threat, as described by Leventhal’s
Self-Regulatory Model [23]. This scale has solid psycho-
metric properties, and has been used with numerous dis-
ease populations, including PLWHA [24,25].
The 22–item Impact of Events Scale-Revised (IES-R) is
used to assess the participant’s level of perceived distress
(during the past 7 days) due to HIV. The IES-R can be
scored to generate three subscales (Avoidance, Intru-
sions, and Hyperarousal) and an overall score. This scale
has solid psychometric properties and has been used
with many diverse populations [26].
Attitudes about smoking
Several measures are used to assess attitudes about
smoking. Quit motivation is assessed with the Reasons
for Quitting questionnaire. This 20-item scale assesses
intrinsic (health concerns, self-control) and extrinsic
(immediate reinforcement, social influence) motives for
quitting smoking. Both intrinsic motives and the ratio of
intrinsic to extrinsic motives have been demonstrated to
predict successful smoking cessation [27,28]. To assess
risk perceptions and outcome expectancies, we devel-
oped a series of items based on recommendations by
Brewer and colleagues [29]. Specifically, participantsrespond to the following four questions, as applicable: 1)
“If you don’t quit or go back to smoking, what are your
chances of ever developing a smoking-related health
problem?”; 2) “If you quit smoking or remain quit, what
are your chances of ever developing a smoking-related
health problem?”; 3) Compared to other smokers, what
are your chances of ever developing a smoking-related
health problem if you continue or go back to smoking?”;
4) Compared to other smokers, what are your chances
of ever developing a smoking-related health problem if
you quit smoking or remain quit?”Perceived control
Three separate measures are used to assess perceived
control. The widely used and well-validated 18-item
Multidimensional Health Locus of Control (MHLC) scale
is used to assess internal and external locus of control
[30,31]. In addition, Treatment Involvement is mea-
sured by a 4-item scale used on the HIV Cost and Ser-
vices Utilization Study [32]. These items measure
desire for information involvement and preference for
decision involvement in one’s own care. Item responses
are scored on a 4-point scale ranging from strongly
agree to strongly disagree [33]. Finally, the 9-item self-
efficacy scale developed and validated by Velicer and
colleagues is administered [34]. This commonly used
self-efficacy scale assesses an individual’s confidence in
his/her ability to not smoke in a variety of situations.Subjective norms
We constructed three sequential questions to assess sub-
jective norms. The questions were constructed based on
the recommendations of Ajzen [35]. An example of these
items is, “My family thinks that it is important for me to
quit smoking”. Identically structured items will substitute
“family” with “friends” and “doctor”. Each item will be
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likely to 7-extremely unlikely.
Intention to quit smoking
Intention to quit smoking is assessed by asking par-
ticipants whether or not they plan to quit smoking.
Responses are entered on a 7-point scale, ranging from
1-definitely no to 7-definietely yes. An additional intention
item considers time frame (i.e., quitting within the next
month - within the next year). Similar items assess
intention to cut back on the number of cigarettes
smoked per day, and time frame for planned reduction.
In addition to these intention items, we assess the par-
ticipant’s readiness to quit with two commonly used mea-
sures: Stage of Change and the Contemplation Ladder.
Stage of Change is a widely used approach that categorizes
individuals into stages (e.g., pre-contemplation, contem-
plation, action, and maintenance) based on past quit at-
tempts and timing of planned future quit attempts [36].
The Contemplation Ladder is a single item that asks re-
spondents to circle a number on a 10-rung ladder that
represents their current level of readiness to consider
smoking cessation [37]. Responses range from 0 (no
thought of quitting) to 10 (taking action to quit smoking,
e.g. cutting down enrolling in a cessation program).
Smoking status
The Smoking Status Questionnaire is a 10-item question-
naire that assesses smoking behavior within the last
seven days, within the last 30 days, and since the time of
last contact. Cigarettes smoked per day, longest period
of abstinence since last contact, number of relapses, use
of nicotine replacement, exposure to other types of to-
bacco, or use of any other cessation treatment (e.g., pro-
fessional assistance and self-help) are also included [38].
Demographic, health, and smoking questionnaires
These items are designed to provide demographic data
(e.g., age, race/ethnicity, education level, income, and oc-
cupation), current medications, current medical care (in-
cluding number and type of healthcare visits), route of
HIV infection, drug/alcohol use, history of depression, and
smoking history (e.g., years smoked, amount smoked, age
of initiation, previous quit attempts, and relapse history).
These items have been used in several of our other smoking
cessation trials as well as in our pilot study [39-41].
Fagerström test for nicotine dependence (FTND)
The original items of the Fagerström Tolerance Question-
naire (FTQ) were derived from theoretical conceptualiza-
tions of reliance on nicotine [42]. The instrument is
reliable and useful in a broad spectrum of populations
[43]. The FTND, a modification of the FTQ, is a 6-item
scale with solid psychometric properties [44].Center of epidemiologic studies depression scale (CES-D)
The CES-D is a 20-item measure developed to assess de-
pressive symptoms in community, non-clinical popula-
tions [45]. This scale consists of four major factors:
depressed affect, enervation, lack of positive affect and
interpersonal problems. Good psychometric properties
have been demonstrated across diverse populations [7].
Positive and negative affect schedule (PANAS)
The PANAS is a 20-item adjective rating form that in-
cludes both positive and negative affect scales. Ratings
are based on a five-point Likert scale (1 = very slightly or
not at all to 5 = extremely). The scales have demon-
strated high reliabilities, and intercorrelations between
the scales are low [46].
Interpersonal support evaluation list (ISEL)
The ISEL is used to measure social support. This 12-item
measure assesses three constructs of social support: tan-
gible, appraisal, and belonging. Social support is a well-
established predictor of successful smoking cessation [47].
AIDS clinical trials group (ACTG) measures
Two measures developed by the ACTG are used to
capture both HIV/AIDS-related symptom status and
HIV medication adherence. The HIV Symptom Index
is a 20-item instrument that assesses the presence of
20 HIV-related symptoms, and the degree to which
these symptoms are distressing to the respondent. The
scale has been validated and correlates with measures
of functional status and HIV disease stage [48]. Using
this measure in our previous work, we have shown
that smoking cessation can significantly reduce symp-
tom burden [49]. The 20-item HIV Medication Adherence
Questionnaire assesses overall adherence to HIV me-
dications, and variables associated with adherence (e.g.,
away from home, side effects, and complication of re-
gimen) [50].
Mental status
We use the Mini-Mental Status Examination (MMSE)
to assess possible cognitive impairment. This brief meas-
ure is widely used in a variety of clinical and research
settings and has been validated in English and Spanish
[51]. See Table 1 for assessment schedule.
General analytic approach
Because we are collecting repeated measurements that
are correlated within subjects, our data analytic ap-
proach utilizes generalized linear mixed model (GLMM)
regression [52,53]. GLMM is a flexible analytic approach
with wide use in health sciences research [54]. It can
handle fixed- and random-effect model parameters, as
well as both nested designs and repeated measures with
Table 1 Assessment schedule




3-month 6-month 9-month 12-month
Brief Illness perception questionnaire (Brief-IPQ) X X X X X X
Impact of events scale (IES-R) X X X X X
Reasons for quitting X X* X X X X
Risk perceptions/qutcome expectancies X X X X X X
Health locus of control (MHLC) X X X X X
Self-efficacy X X X X X
Treatment involvement X X X X X
Subjective norms X X X X X
Intention to quit smoking X X* X X X X
Contemplation ladder X X X X X
Stage of change X X X X X
Smoking status (self-report) X* X X X X
Demographics and health hehaviors X X* X* X* X*
Fagerström test for nicotine dependence (FTND) X X X X X
Center of epidemiologic studies depression scale (CES-D) X X X X X
Positive and negative affect schedule (PANAS) X X X X X
Interpersonal support evaluation list (ISEL) X X X X X
ACTG symptom status X X X X X
ACTG medication adherence X X X X
Expired carbon monoxide X X X X X
Mini-mental status examination (MMSE) X X X X X
*Brief version.
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handle normal and non-normal outcomes (such as the
dichotomous outcome of smoking cessation), different
variance functions, as well as unbalanced designs where
the number of repeated measurements varies across
individuals.
Statistical analysis
Aim 1 is to assess the relationship between HIV disease
event/stage (i.e., diagnosis, stable, and progressive dis-
ease) and smoking outcomes (i.e., intention to quit,
number of quit attempts, and cessation outcomes). To
evaluate Specific Aim 1, we will assess each of the pair-
wise comparisons between the three disease events/stages.
For the primary analysis, intention to quit smoking will be
classified as a dichotomous endpoint. Specifically, partici-
pants who have either quit smoking or report high levels
of intention to quit smoking (i.e., scores of 5–7 on the 7-
point intention-to-quit scale) will be compared to partici-
pants who do not intend to quit (i.e., current smokers with
scores of 1–4 on the intention to quit scale). A GLMM
with binomial error distribution and logit link function
will be used for this analysis. The same analysis will be
used for the binary cessation outcome. In this model, wewill use 7-day point prevalence abstinence as our out-
come. That is, participants who self-report no smoking
(not even a puff) in the past seven days and have an ex-
pired CO level of < 10 ppm will be considered abstinent.
Similarly, the number of quit attempts (i.e., trying to quit
and remaining abstinent for ≥ 24 hours) will be analyzed
using a Poisson mixed effects model, a special class of
GLMMs, and continuous cessation outcomes will be ana-
lyzed using a linear mixed model.
Aim 2 is to evaluate perceived impact of HIV as a po-
tential mediator of the association between disease stage
and smoking outcomes. We will assess the indirect ef-
fects of disease event/stage on smoking outcomes (bin-
ary, ordinal or continuous) through perceived impact of
HIV, not necessarily requiring that a significant associ-
ation between disease event/stage and smoking out-
comes be found, as long as the hypothesized theory in
our conceptual framework calls for the analysis. This strat-
egy is consistent with new recommendations regarding
mediation analysis in social psychology [55]. Exploratory
analyses will also be performed to assess the mediation
and/or moderation effects of all the constructs in the con-
ceptual framework. To assess the mediation effects, we
will use the approaches of MacKinnon and colleagues and
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lar, we will use a bootstrap resampling approach to cal-
culate the confidence intervals of the indirect effects.
Moreover, for binary and ordinal outcomes, we will fol-
low the approaches recommended by MacKinnon and
colleagues [57,61].
Aim 3 is to evaluate potential mediators (i.e., attitudes
about smoking) and moderators (i.e., perceived control
and social norms) of the relationship between perceived
impact of HIV disease and smoking outcomes. We will
assess the indirect effects of perceived impact of HIV on
smoking outcomes through attitudes about smoking.
Similar procedures for testing for mediation effects for
Specific Aim 2 will be employed in assessing Specific Aim
3. In addition, we will assess whether perceived control
and social norms moderate the above association, by in-
cluding and testing the interaction between these variables
and the perceived impact of HIV in the GLMMs. A sig-
nificant interaction effect will indicate the presence of a
moderation effect.
Aim 4 is to describe, in detail, the smoking behavior of
individuals recently diagnosed with HIV within the first
three months after study enrollment. For Specific Aim 4,
we expect that the probability of intention to quit smok-
ing will decrease over the three-month period after ini-
tial diagnosis. A series of GLMMs will be generated. We
will first use GLMM to model parametric time profiles
of this smoking behavior. In the event that the data sug-
gest a nonlinear trajectory, nonparametric or nonlinear
regression models for longitudinal data will be explored
or employed. In particular, models that may be useful in-







Figure 2 CONSORT diagram of Project STATE: screening, study enroll[63], and Li et al. [64]. These methods are applicable to
normal (continuous) or non-normal (e.g., categorical)
smoking outcome data. Estimation of such time profiles
will allow us to determine the teachable moment’s mag-
nitude and duration in this critical period of time follow-
ing HIV diagnosis. In the second step, separate models
will be generated to explore the effects of perceived im-
pact of HIV, risk perception, and quit motivation, in
addition to time, on quit intention. A final step will in-
clude all three predictor variables in a single model. It
should also be noted that potential confounders (e.g.,
smoking cessation treatment) will be controlled in each
step. We will perform a similar series of analyses to con-
sider current smoking status.
Missing data and drop-outs
Some participants will fail to complete all planned as-
sessments and consequently present missing data. For
missing smoking outcomes, we will use a conservative
approach of treating missing intention-to-quit or cessa-
tion outcome data as no intention to quit smoking, or
imputing the number of quit attempts with the currently
observed number (i.e., no improvement after that). While
this generally is considered a conservative approach, we
note that GLMM will give unbiased estimates of effects
provided that the probability of having missing data de-
pends only on the observed variables in the model (or are
missing at random [MAR]). We will conduct additional
sensitivity analyses assuming different missing data mecha-
nisms. For example, we will consider a multiple imputation
approach based on relevant patient characteristics at base-
line to account for potential missing at random (MAR)d assessed for 
=1,557)
Excluded (n=1,017)
Did not meet inclusion criteria (n=930) 
Declined to participate (n=87)
Met inclusion criteria, but not enrolled (n=137) 
Lack of time (n=131)
Other reasons (n=6)
d (n=403)






ment, and retention through 12-month follow-up.
Table 2 Baseline characteristics of study participants
Demographic, psychosocial and smoking variables n = 384
Mean age in years (SD) 38.7 (10.6)
Male, n (%) 280 (72.9)
Married/living with significant other, n (%) 70 (18.2)
Race/ethnicity, n (%)
White 69 (18.0)
Black/African American 245 (63.8)
Latino/Hispanic 56 (14.6)
Other 14 (3.6)
Mean years of formal education (SD) 10.9 (4.0)
Education level, n (%)
Less than high school 139 (36.2)
High school or equivalent 150 (39.1)
More than high school 95 (24.7)
Current employment status, n (%)
Working full or part time 63 (16.4)
Not working due to health 185 (48.2)
Unable to find work 95 (24.7)
Not working for other reasons 41 (10.7)
HIV transmission, n (%)
Male homosexual contact 132 (34.4)
Heterosexual contact (45.6)
Injection drug use 35 (9.1)
Other 42 (10.9)
Depression (CES-D score1), mean (SD) 22.1 (11.8)
Cigarettes smoked per day, n (%)
10 or fewer 231 (60.2)
11 to 20 per day 117 (30.5)
21 to 30 per day 19 (4.9)
31 or more per day 17 (4.4)
Nicotine dependence (FTND score2), mean (SD) 4.3 (2.5)
Alcohol use (AUDIT score3), mean (SD) 8.6 (7.6)
Illicit drug use in past 30 days, n (%) 178 (46.4)
1Range 0-60, scores ≥16 indicate risk of clinical depression.
2Range, 0–10.
3Scores ≥8 are associated with harmful or hazardous drinking.
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lection models to account for potential missing not at ran-
dom (MNAR) mechanisms [65]. Similar findings based on
these analyses will strengthen our study conclusions.
Power and sample size
We present a power analysis for Primary Aim 1 based on
several conservative estimations. Specifically, the following
assumptions are made: 1) Approximately 50% of patients
will intend to quit smoking at the time of initial HIV diag-
nosis. This is based on earlier reports that >50% of HIV
patients report adopting healthier behaviors following an
HIV diagnosis [33]. At each follow-up visit, patients will
be classified as having stable HIV disease or progressive
HIV disease based upon their viral load, CD4 count and
presence of AIDS-defining illnesses; 2) It is anticipated
that 30% of participants will meet the criteria for progres-
sive disease in the 12-month follow-up window.
We will enroll 450 participants in the study, and con-
servatively estimate that 20% of these participants will
miss at least one of the four (i.e., 3-, 6-, 9-, and 12-
month) follow-up measurements. Assuming that 50% of
participants will quit or intend to quit at diagnosis, using
a logistic mixed model analysis we will have 87% power
to detect a rate to quit or intent to quit of 39% or lower
in progressive disease and 99% power to detect a rate of
30% in patients with stable disease. We will have 88%
power to detect the difference between 30% and 39% in
the stable and progressive arms. Conservatively, we have
chosen to base our power estimates on a dichotomous
outcome, as described above. Power will generally be
higher when the outcome variable is ordinal or continu-
ous. Therefore, we will have excellent power to detect
moderate effect sizes for Primary Aim 1.
Discussion
Efforts to develop and assess novel smoking cessation
treatments for underserved HIV-positive populations are
needed. By evaluating events/stages of HIV disease as
potential teaching moments for smoking cessation, find-
ings from this study could be used to develop treatments
tailored to an individual’s stage of HIV disease. We expect
that disease events/stages will influence perceived impact
of HIV disease which will, in turn, influence smoking re-
lated attitudes and behavior. For example, if individuals
are more likely to be motivated to make a quit attempt
at the time of HIV diagnosis, efforts to target individ-
uals at this time with relatively low intensity treatments
may be quite effective. On the other hand, treatments
targeting individuals with stable HIV disease - who may
have relatively low levels of motivation to quit - may re-
quire greater intensity.
Thus far, we have successfully consented 403 participants.
See Figure 2 for the CONSORT (Consolidated Standards ofReporting Trials) diagram which displays participant
recruitment, enrollment and follow-up to date. Study par-
ticipants are predominantly male (72.9%), Black/African-
American (63.8%), have completed 10.9 years of formal
education, were infected through heterosexual contact
(45.6%), are smoking 10 or fewer cigarettes per day (60.2%)
and have a mean age of 38.7 years. See Table 2 for complete
demographic and psychosocial and smoking variables of
study participants.
This prospective study design enables us to carefully
track changes in smoking behavior over time, and to link
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or to the participant’s perceived impact of HIV. By
identifying optimal time points for intervention, the
findings from this study will have the potential to
maximize the efficiency and efficacy of cessation treat-
ments delivered in resource-limited settings. In addition,
the findings will be instrumental in identifying specific
constructs that should be targeted for intervention and
will provide a strong foundation for the development of
future cessation interventions targeting smokers living
with HIV/AIDS.
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